Introduction
============

Pantoprazole is one of the proton pump inhibitor agents, which was first introduced in 1994. Pantoprazole and other proton pump inhibitors (PPIs) reduce acid production and its indications are treatment of erosive gastritis, esophagitis, gastric ulcer, duodenal ulcer and Zollinger Ellison syndrome ([@B1]). Many side effects have been reported following pantoprazol usage but it has rarely been reported as a cause of anaphylaxis. Here, we present a case of anaphylactic reaction to intravenous pantoprazole in a young woman who had presented to emergency department following epigastric pain.

Case presentation
=================

The case is a 21-year-old woman who was brought to emegency department of Amiralmomenin Hospital, Maragheh, Iran, with epigastric pain, which had started 2 days before. The pain was localized, did not radiated to anywhere, and was slightly relived with eating and exacerbated after half an hour. She did not have bloody vomit or Melena. She had loose defecation three times a day. Vital signs were as follow: blood pressure = 80/120 mmHg, heart rate = 72 beat/minute, respiratory rate = 14 beat/minute, and arterial oxygen saturation =94% in room air.

After careful history taking and clinical examination, the patient was diagnosed as gastritis. Intravenous line was accessed and she was treated with 40 mg intravenous pantoprazole. 2 minutes after drug administration, the patient was symptomatic with hives, dyspnea and cyanosis and her blood pressure had decreased to 85/60 mmHg, heart rate increased to 101/minute, and oxygen saturation to 78% in room air.

She was immediately treated as anaphylactic shock with normal saline (30cc/kg), intramuscular epinephrine (0.3 mg), interavenous hydrocortisone (100 mg) and chlorpheniramin (4 mg). 6 lit/minute oxygen was administered via an oxygen mask. Gradually, her general condition improved and after 2 hours, the general condition completely was recovered. She was discharged after 12 hours.

Discussion
==========

Several complications such as headache, dizziness, joint pain, nausea, vomiting, abdominal pain, increased risk of stomach and pancreatic cancer, acute interstitial nephritis, diarrhea, risk of fractures, vitamin B 12 deficiency, hypomagnesaemia, fever, hypertensive pneumonitis, liver damage, severe acute hepatitis, Kounis syndrome and thrombocytopenia have been reported following usage of PPIs ([@B1]-[@B10]). Acute and delayed allergic reactions and systemic reactions have been reported in rare cases, even with oral doses of pump inhibitor drugs ([@B11]-[@B14]). There are occasional cross-reactions between different drugs in this group ([@B14]). Our search in literature shows that a few cases of anaphylaxis to PPI have been reported ([@B14]-[@B16]), and our case is another report of anaphylaxis to pantoprazole. Anaphylatic reaction to PPIs is reported with both oral and IV routes of administration ([@B17], [@B18]).

Hou-Chuan Lai et al. presented a case of anaphylaxis to IV pantoprazole in a 50 year-old male patient during general anesthesia, who was discharged after successful resuscitation ([@B19]).

V. Vovolis et al. in a study in 2008 showed that skin test with PPIs could be considered as an accurate and simple method of evaluating the cross reaction between drugs of this group ([@B20]).

Anaphylactic reaction to PPIs is rare but, like other causes of anaphylactic shock, it is life treatining. It seems that emergency phycisians should be aware of this problem and take care of the patients in case of this reaction happening.
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